Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in adolescent schizophrenia
NCT04779177Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumateperone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Intra-Cellular Therapies. Primary endpoints: Maximum Plasma Concentration at Day 5, Time to Maximum Plasma Concentration at Day 5 and 4 more. Started Mar 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04779177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779177.